Bliss GVS Pharma Share Price | Bliss GVS Pharma Stock Screener
BLISSGVS
Pharmaceuticals
Share Price NSE
₹396.85
▲
15.80 (4.15%)
Share Price BSE
₹396.35
▲
15.25 (4.00%)
As of May 27, 2026, the Bliss GVS Pharma share price (NSE: BLISSGVS) is ₹396.85 on NSE and ₹396.35 on BSE, up 4.15% from the previous close, with shares trading between ₹375.00 and ₹399.60, and a 52-week range of ₹127.90–₹396.85.
Check BLISSGVS price range for the annual price range and momentum.
Use the Bliss GVS Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Bliss GVS Pharma Market Cap
₹4,198.24 Cr.
BLISSGVS P/E Ratio (TTM)
29.91
Bliss GVS Pharma P/B Ratio
3.38
EPS (TTM)
₹12.23
Dividend Yield
0.26%
Debt to Equity
0.09
BLISSGVS 52 Week High
₹396.85
Bliss GVS Pharma 52 Week Low
₹127.90
Operating Margin
17.00%
Profit Margin
13.81%
BLISSGVS Revenue (TTM)
₹268.00
EBITDA
₹56.00
Net Income
₹37.00
Total Assets
₹1,492.00
Total Equity
₹1,193.00
Bliss GVS Pharma Share Price Chart
Screen Bliss GVS Pharma share price with an interactive chart. Analyse BLISSGVS price trends and volatility across different timeframes.
Bliss GVS Pharma Company Profile - Fundamental Screener
Screen Bliss GVS Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for BLISSGVS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE416D01022
Bliss GVS Pharma Balance Sheet Screener
Screen BLISSGVS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,492 | 1,301 | 1,212 | 1,157 | 1,109 | 1,077 | 1,027 | 905 | 860 | 1,023 |
| Current Assets | 946 | 827 | 811 | 697 | 777 | 765 | 770 | 694 | 690 | 566 |
| Fixed Assets | 458 | 406 | 370 | 379 | 282 | 234 | 242 | 146 | 143 | 305 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 25 | 37 | 51 | 46 | 29 | 45 | 46 | 38 | 13 | 33 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,193 | 1,092 | 1,003 | 917 | 847 | 828 | 750 | 660 | 548 | 553 |
| Share Capital | 11 | 11 | 11 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves & Surplus | 1,182 | 1,040 | 957 | 874 | 808 | 798 | 725 | 636 | 526 | 476 |
Bliss GVS Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Bliss GVS Pharma income statement and profit fundamentals.
Analyze BLISSGVS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Bliss GVS Pharma share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 268 | 210 | 243 | 253 | 237 | 204 | 188 | 223 | 226 | 188 | 165 | 225 | 206 | 179 | 196 |
| Expenses | 213 | 177 | 166 | 201 | 186 | 199 | 149 | 176 | 181 | 179 | 135 | 158 | 157 | 147 | 150 |
| EBITDA | 56 | 33 | 77 | 52 | 51 | 5 | 39 | 47 | 45 | 9 | 29 | 67 | 49 | 32 | 46 |
| Operating Profit % | 17.00% | 11.00% | 20.00% | 18.00% | 15.00% | 0.00% | 19.00% | 19.00% | 14.00% | 3.00% | 15.00% | 26.00% | 22.00% | 12.00% | 21.00% |
| Depreciation | 9 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 8 | 5 | 6 | 6 | 7 | 4 | 5 |
| Interest | 2 | 2 | 6 | 3 | 2 | 2 | 2 | 4 | 1 | 5 | 2 | 2 | 2 | 2 | 2 |
| Profit Before Tax | 45 | 23 | 63 | 41 | 41 | -4 | 30 | 36 | 36 | -1 | 22 | 59 | 40 | 27 | 39 |
| Tax | 8 | 7 | 19 | 12 | 16 | 1 | 8 | 10 | 11 | -4 | 7 | 16 | 11 | 3 | 12 |
| Net Profit | 37 | 17 | 44 | 29 | 25 | -5 | 22 | 26 | 26 | 4 | 14 | 43 | 29 | 24 | 28 |
| EPS | 3.22 | 1.47 | 4.08 | 2.58 | 2.20 | -0.88 | 1.97 | 2.31 | 2.27 | 0.34 | 1.41 | 4.06 | 2.64 | 1.90 | 2.48 |
Bliss GVS Pharma Cash Flow Screener - Liquidity Fundamentals
Screen BLISSGVS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 106 | 103 | 34 | 136 | 64 | 47 | 40 | 18 | 290 | 113 |
| Investing Activities | -75 | -83 | -6 | -103 | -45 | -40 | -79 | 48 | -249 | -50 |
| Financing Activities | -30 | -21 | -25 | -24 | -21 | -6 | 17 | -76 | -10 | -40 |
| Net Cash Flow | 0 | -1 | 3 | 9 | -2 | 0 | -22 | -11 | 30 | 23 |
Bliss GVS Pharma Shareholding Pattern Screener
See Bliss GVS Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Bliss GVS Pharma promoter holding and ownership changes for BLISSGVS on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 35.36% | 35.36% | 35.39% | 35.44% | 35.29% | 35.10% | 34.82% | 34.90% |
| FII Holding | 10.45% | 14.54% | 13.27% | 12.65% | 13.18% | 13.51% | 12.13% | 13.25% |
| DII Holding | 5.04% | 5.78% | 5.98% | 6.54% | 6.55% | 6.55% | 6.57% | 6.58% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 32.60% | 31.48% | 32.85% | 32.79% | 32.63% | 32.93% | 34.57% | 32.84% |
| Other Holding | 16.55% | 12.84% | 12.51% | 12.58% | 12.34% | 11.91% | 11.92% | 12.43% |
| Shareholder Count | 44,874 | 43,380 | 44,461 | 46,707 | 49,517 | 49,558 | 52,937 | 44,737 |
Bliss GVS Pharma Share Dividend Screener - Share Yield Analysis
Check Bliss GVS Pharma dividend history with payout and yield data.
View Bliss GVS Pharma dividend details including ex-dates and amounts for BLISSGVS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.50 | 0.23% |
| 2024-March | ₹0.50 | 0.42% |
| 2023-March | ₹0.50 | 0.44% |
| 2022-March | ₹0.50 | 0.71% |
| 2021-March | ₹0.50 | 0.65% |
| 2020-March | ₹0.50 | 0.51% |
| 2019-March | ₹1.00 | 0.99% |
| 2018-March | ₹1.00 | 0.56% |
| 2017-March | ₹0.60 | 0.31% |
Bliss GVS Pharma Stock Index Membership
See which indices include Bliss GVS Pharma stock.
Check BLISSGVS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX BSE HC
BSE INDEX SMLCAP
Bliss GVS Pharma Market Events Screener - Corporate Actions
Get Bliss GVS Pharma corporate actions including splits, bonuses, and buybacks.
Check Bliss GVS Pharma stock events that may affect BLISSGVS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 0.50 /share | -9.72% | ||
| 2026-07-15 | 2026-07-15 | Annual General Meeting | NA | 40.48% |
| 2026-05-12 | 2026-05-12 | Quarterly Result Announcement | NA | -1.04% |
| 2026-02-18 | 2026-02-18 | Dividend | ₹ 0.50 /share | 13.60% |
| 2026-02-10 | 2026-02-10 | Quarterly Result Announcement | NA | 17.93% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | 1.19% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 63.78% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -4.19% |
| 2025-07-24 | 2025-07-24 | Dividend | ₹ 0.50 /share | 40.29% |
| 2025-05-12 | 2025-05-12 | Quarterly Result Announcement | NA | -5.06% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -13.24% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -0.92% |
| 2024-07-25 | 2024-07-25 | Annual General Meeting | NA | -1.94% |
| 2024-07-18 | 2024-07-19 | Dividend | ₹ 0.50 /share | -9.96% |
| 2023-07-19 | 2023-07-19 | Annual General Meeting | NA | 21.42% |
Bliss GVS Pharma Competitors Screener - Peer Comparison
Screen BLISSGVS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 442,509 | 38.37 | 58,220 | 6.38% | 11,565 | 54.66 |
| Divis Laboratories | 180,452 | 69.82 | 10,560 | 8.73% | 2,520 | 59.28 |
| Torrent Pharmaceuticals | 153,580 | 70.46 | 13,753 | 19.18% | 2,028 | 60.91 |
| Cipla | 114,559 | 29.64 | 27,712 | -2.46% | 3,783 | 64.86 |
| Dr Reddys Laboratories | 110,089 | 26.69 | 33,593 | -0.44% | 3,998 | 54.22 |
| Zydus Life Science | 109,257 | 21.19 | 26,720 | 13.65% | 5,242 | 75.42 |
| Lupin | 104,041 | 19.33 | 27,488 | 19.98% | 5,345 | 46.91 |
| Mankind Pharma | 99,915 | 51.52 | 14,278 | 12.03% | 1,750 | 55.29 |
| Aurobindo Pharma | 83,397 | 24.27 | 33,385 | 3.21% | 3,376 | 47.24 |
| Laurus Labs | 74,592 | 83.31 | 6,813 | 21.03% | 884 | 80.70 |
Bliss GVS Pharma Company Announcements - News Screener
Screen BLISSGVS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-27 | Public Announcement | - |
| 2026-05-25 | Disclosure under Regulation 30A of LODR | - |
| 2026-05-25 | Board Meeting Outcome for Outcome Of Board Meeting Held On May 23 2026 | - |
| 2026-05-25 | Public Announcement In Relation To Open Offer To Public Shareholders (As Defined Under Public Announcement) Of The Company Under SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011 | - |
| 2026-05-23 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-05-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-12 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-12 | Corporate Action-Board approves Dividend | - |
| 2026-05-12 | Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019 | - |
| 2026-05-12 | Audited Standalone & Consolidated Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-05-12 | Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday May 12 2026 | - |
| 2026-05-12 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-05-12 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-05-05 | Board Meeting Intimation for Approval Of Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended March 31 2026 And Recommendation Of Final Dividend If Any For The Year Ended March 31 2026. | - |
| 2026-04-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-09 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-04-08 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-04-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-03 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |